Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
Noosa News8 hours agoTwo teenagers and two adults rushed to hospital in life-threatening conditions after shocking Lawnton house fire
-
General24 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
Noosa News8 hours agoFatal traffic crash, Noosa – Sunshine Coast
-
Noosa News10 hours agoA secret scheme and plans to expel former leaders — here’s what we’ve heard from Queensland’s inquiry into the CFMEU